A randomized clinical trial in which both longitudinal and survival data were collected to compare the efficacy and safety of two antiretroviral drugs in treating patients who had failed or were intolerant of zidovudine (AZT) therapy.
A data frame with 1408 observations on the following 9 variables.
patientpatients identifier; in total there are 467 patients.
Timethe time to death or censoring.
deatha numeric vector with 0 denoting censoring and 1 death.
CD4the CD4 cells count.
obstimethe time points at which the CD4 cells count was recorded.
druga factor with levels ddC denoting zalcitabine and ddI denoting didanosine.
gendera factor with levels female and male.
prevOIa factor with levels AIDS denoting previous opportunistic infection (AIDS
diagnosis) at study entry, and noAIDS denoting no previous infection.
AZTa factor with levels intolerance and failure denoting AZT intolerance and
AZT failure, respectively.
Goldman, A., Carlin, B., Crane, L., Launer, C., Korvick, J., Deyton, L. and Abrams, D. (1996) Response of CD4+ and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 11, 161--169.
Guo, X. and Carlin, B. (2004) Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician 58, 16--24.